In short
Clinical trials of Ligelizumab are studying people with food allergy to see how safe and tolerable the treatment is over time. The trial data focus on long-term safety, including unwanted medical events, in a large group of participants. This article summarizes what was studied, who took part, and the main trial endpoint.
Key points
- Ligelizumab clinical trial data here focus on people with food allergy. The study is a Phase 3, interventional, long-term extension study with 550 participants. Its main purpose was to evaluate long-term safety and tolerability. The primary endpoint measured treatment-emergent adverse events and serious adverse events, including rates adjusted for time in the study. The trial was completed.
Trial overview
The available trial data describe a long-term extension study of Ligelizumab in people with food allergy. This means the study followed participants for a longer time to learn more about safety and tolerability.
Who participated
The study population was people with food allergy. The trial data do not give more detailed entry rules in the source provided, so the main target group we can confirm is participants with this condition.
What was studied
The trial was designed to evaluate the long-term safety and tolerability of Ligelizumab in participants with food allergy. In simple terms, the researchers wanted to see how well people handled the study treatment over time and whether any medical problems appeared during treatment.
The intervention list in the source includes Ligelizumab listed as QGE031 in the study materials. The source also lists placebo and rescue or support medicines such as epinephrine and salbutamol, but it does not explain how each was used in the study design.
Main outcome measured
The primary outcome was the overall incidence and exposure-adjusted occurrence rates of treatment-emergent adverse events and serious adverse events. This means the study counted medical problems that started during treatment and also adjusted the results for how long people stayed in the study.
Adverse events are unwanted medical problems, and serious adverse events are the more severe ones. The trial focused on these safety measures rather than on symptom relief or cure.
Study design and phase
This was an interventional trial, which means the researchers gave a study treatment and then measured what happened. The trial was in Phase 3, which is a later stage of clinical research with a larger number of participants.
The study was also a long-term extension, so it appears to have continued observation after earlier research in the same program. The source does not provide the earlier trial details, so only the extension study can be described here.
Trial status and size
The trial status is listed as Completed. The enrollment was 550 participants, showing that this was a fairly large food allergy study.
Because the source data are limited to one trial record, the article cannot describe results beyond the stated safety objective and endpoint.